– Conf Call
Newly Listed Migraine-Focused AEON Biopharma Stock Plunges On Friday – Read Here Why
Preliminary results of AEON Biopharma's Phase 2 trial for chronic migraine treatment reveal no significant improvement over placebo. Despite anticipated reductions in monthly migraine days, statistical significance was not reached, prompting a review of development strategies and financial measures.
